The Pre-Approval Inspection (PAI) was completed on February 13, 2026, and the company is initiating corrective actions.
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
The new functionality complements Parse’s existing Evercode immune products
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The funding will accelerate Sinopia’s data-driven drug discovery efforts
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
